Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.01 par value
-
Shares outstanding
-
125,955,831
-
Number of holders
-
11
-
Total 13F shares, excl. options
-
218,521
-
Shares change
-
-143,718
-
Total reported value, excl. options
-
$126,742
-
Value change
-
-$84,498
-
Number of buys
-
6
-
Number of sells
-
-9
-
Price
-
$0.58
Significant Holders of NovaBay Pharmaceuticals, Inc. - Common Stock, $0.01 par value (NBY) as of Q2 2025
17 filings reported holding NBY - NovaBay Pharmaceuticals, Inc. - Common Stock, $0.01 par value as of Q2 2025.
NovaBay Pharmaceuticals, Inc. - Common Stock, $0.01 par value (NBY) has 11 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 218,521 shares
of 125,955,831 outstanding shares and own 0.17% of the company stock.
Largest 10 shareholders include C2C Wealth Management, LLC (98,000 shares), GEODE CAPITAL MANAGEMENT, LLC (33,823 shares), Rangeley Capital, LLC (33,210 shares), TWO SIGMA SECURITIES, LLC (24,280 shares), XTX Topco Ltd (20,310 shares), Tower Research Capital LLC (TRC) (5,451 shares), UBS Group AG (3,385 shares), BANK OF AMERICA CORP /DE/ (55 shares), NVWM, LLC (3 shares), and MORGAN STANLEY (3 shares).
This table shows the top 11 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.